ES2258171T3 - Composiciones farmaceuticas de agonista parcial de 5ht4. - Google Patents
Composiciones farmaceuticas de agonista parcial de 5ht4.Info
- Publication number
- ES2258171T3 ES2258171T3 ES02796711T ES02796711T ES2258171T3 ES 2258171 T3 ES2258171 T3 ES 2258171T3 ES 02796711 T ES02796711 T ES 02796711T ES 02796711 T ES02796711 T ES 02796711T ES 2258171 T3 ES2258171 T3 ES 2258171T3
- Authority
- ES
- Spain
- Prior art keywords
- composition according
- tegaserod
- mixture
- procedure
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403339A EP1321142A1 (en) | 2001-12-21 | 2001-12-21 | Solid pharmaceutical composition for oral administration of Tegaserod |
| EP01403339 | 2001-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2258171T3 true ES2258171T3 (es) | 2006-08-16 |
Family
ID=8183045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02796711T Expired - Lifetime ES2258171T3 (es) | 2001-12-21 | 2002-12-20 | Composiciones farmaceuticas de agonista parcial de 5ht4. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050106236A1 (https=) |
| EP (2) | EP1321142A1 (https=) |
| JP (1) | JP4718776B2 (https=) |
| KR (1) | KR100980144B1 (https=) |
| CN (1) | CN100464749C (https=) |
| AR (1) | AR037937A1 (https=) |
| AT (1) | ATE320807T1 (https=) |
| AU (1) | AU2002361198B2 (https=) |
| BR (1) | BR0215148A (https=) |
| CA (1) | CA2470668C (https=) |
| CO (1) | CO5640102A2 (https=) |
| CY (1) | CY1105559T1 (https=) |
| DE (1) | DE60210139T2 (https=) |
| DK (1) | DK1458377T3 (https=) |
| EC (1) | ECSP105163A (https=) |
| EG (1) | EG24194A (https=) |
| ES (1) | ES2258171T3 (https=) |
| HU (1) | HU226589B1 (https=) |
| IL (2) | IL162451A0 (https=) |
| MX (1) | MXPA04006157A (https=) |
| MY (1) | MY139546A (https=) |
| NO (1) | NO20042779L (https=) |
| NZ (1) | NZ533585A (https=) |
| PE (1) | PE20030872A1 (https=) |
| PL (1) | PL369509A1 (https=) |
| PT (1) | PT1458377E (https=) |
| RU (1) | RU2322978C2 (https=) |
| SI (1) | SI1458377T1 (https=) |
| TW (1) | TWI260221B (https=) |
| WO (1) | WO2003053432A1 (https=) |
| ZA (1) | ZA200404467B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1314185B1 (it) * | 1998-08-21 | 2002-12-06 | Novartis Ag | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi |
| SG168407A1 (en) | 2003-01-28 | 2011-02-28 | Ironwood Pharmaceuticals Inc | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20050119328A1 (en) * | 2003-03-25 | 2005-06-02 | Hetero Drugs Limited | Novel crysalline forms of tegaserod maleate |
| EP1629280A2 (en) * | 2003-05-21 | 2006-03-01 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4) |
| AR045081A1 (es) * | 2003-07-24 | 2005-10-12 | Novartis Ag | Modificaciones estables de maleato de hidrogeno de tegaserod |
| ES2655435T3 (es) | 2003-09-12 | 2018-02-20 | Amgen Inc. | Formulación de disolución rápida de cinacalcet |
| KR20060111675A (ko) * | 2003-12-16 | 2006-10-27 | 테바 파마슈티컬 인더스트리즈 리미티드 | 테가세로드 염기 및 그것의 염의 다형태 |
| CZ298399B6 (cs) * | 2005-05-02 | 2007-09-19 | Zentiva, A. S. | Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu) |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| SI2384318T1 (en) | 2008-12-31 | 2018-03-30 | Ardelyx, Inc. | MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| MX366293B (es) | 2012-08-21 | 2019-07-04 | Ardelyx Inc | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| LT2983667T (lt) | 2013-04-12 | 2019-07-10 | Ardelyx, Inc. | Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai |
| CN104922083B (zh) * | 2015-04-15 | 2017-12-22 | 湖南尔康湘药制药有限公司 | 磺胺嘧啶片及其制备方法 |
| WO2017064538A1 (en) * | 2015-10-16 | 2017-04-20 | Nobel Ilac Sanayii Ve Ticaret A.S. | Pharmaceutical compositions of nilotinib hydrochloride |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| CA3049678A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
| JPH09194374A (ja) * | 1995-11-14 | 1997-07-29 | Taisho Pharmaceut Co Ltd | 消化器疾患治療剤 |
| DE69713948D1 (de) * | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| IT1314185B1 (it) * | 1998-08-21 | 2002-12-06 | Novartis Ag | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| WO2000057857A1 (en) * | 1999-03-25 | 2000-10-05 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| EA004872B1 (ru) * | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
-
2001
- 2001-12-21 EP EP01403339A patent/EP1321142A1/en not_active Withdrawn
-
2002
- 2002-12-17 EG EG2002121358A patent/EG24194A/xx active
- 2002-12-19 TW TW091136675A patent/TWI260221B/zh not_active IP Right Cessation
- 2002-12-19 AR ARP020105024A patent/AR037937A1/es not_active Application Discontinuation
- 2002-12-20 PT PT02796711T patent/PT1458377E/pt unknown
- 2002-12-20 AT AT02796711T patent/ATE320807T1/de active
- 2002-12-20 KR KR1020047009594A patent/KR100980144B1/ko not_active Expired - Fee Related
- 2002-12-20 DK DK02796711T patent/DK1458377T3/da active
- 2002-12-20 CA CA2470668A patent/CA2470668C/en not_active Expired - Fee Related
- 2002-12-20 JP JP2003554189A patent/JP4718776B2/ja not_active Expired - Fee Related
- 2002-12-20 CN CNB028255321A patent/CN100464749C/zh not_active Expired - Fee Related
- 2002-12-20 US US10/499,721 patent/US20050106236A1/en not_active Abandoned
- 2002-12-20 SI SI200230334T patent/SI1458377T1/sl unknown
- 2002-12-20 WO PCT/EP2002/014674 patent/WO2003053432A1/en not_active Ceased
- 2002-12-20 EP EP02796711A patent/EP1458377B1/en not_active Expired - Lifetime
- 2002-12-20 HU HU0402492A patent/HU226589B1/hu not_active IP Right Cessation
- 2002-12-20 NZ NZ533585A patent/NZ533585A/en not_active IP Right Cessation
- 2002-12-20 ES ES02796711T patent/ES2258171T3/es not_active Expired - Lifetime
- 2002-12-20 RU RU2004122631/15A patent/RU2322978C2/ru not_active IP Right Cessation
- 2002-12-20 MX MXPA04006157A patent/MXPA04006157A/es active IP Right Grant
- 2002-12-20 DE DE60210139T patent/DE60210139T2/de not_active Expired - Lifetime
- 2002-12-20 PL PL02369509A patent/PL369509A1/xx not_active Application Discontinuation
- 2002-12-20 AU AU2002361198A patent/AU2002361198B2/en not_active Ceased
- 2002-12-20 IL IL16245102A patent/IL162451A0/xx active IP Right Grant
- 2002-12-20 MY MYPI20024825A patent/MY139546A/en unknown
- 2002-12-20 BR BR0215148-0A patent/BR0215148A/pt not_active IP Right Cessation
-
2003
- 2003-01-06 PE PE2003000004A patent/PE20030872A1/es not_active Application Discontinuation
-
2004
- 2004-06-07 ZA ZA200404467A patent/ZA200404467B/en unknown
- 2004-06-10 IL IL162451A patent/IL162451A/en not_active IP Right Cessation
- 2004-07-01 NO NO20042779A patent/NO20042779L/no not_active Application Discontinuation
- 2004-07-15 CO CO04067463A patent/CO5640102A2/es not_active Application Discontinuation
-
2006
- 2006-05-04 CY CY20061100579T patent/CY1105559T1/el unknown
-
2008
- 2008-10-07 US US12/287,232 patent/US20090104263A1/en not_active Abandoned
-
2010
- 2010-06-16 EC EC2010005163A patent/ECSP105163A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2258171T3 (es) | Composiciones farmaceuticas de agonista parcial de 5ht4. | |
| ES2393640T3 (es) | Comprimidos bucodisgregables | |
| ES2370943T3 (es) | Composiciones farmacéuticas estabilizadas que comprenden fesoterodina. | |
| JP5409382B2 (ja) | 口腔内崩壊錠 | |
| ES2622495T3 (es) | Composición farmacéutica que contiene un antagonista de canales de calcio de dihidropiridina y método para su preparación | |
| US20100016322A1 (en) | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same | |
| WO2007086457A1 (ja) | 乾式直打速崩壊性錠剤 | |
| JPWO2013047353A1 (ja) | ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠 | |
| ES2582012T3 (es) | Composiciones farmacéuticas de levetiracetam | |
| US9675551B2 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
| EP3679927A1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| JP6116847B2 (ja) | シクロデキストリンとの混合体を含有する錠剤 | |
| EP3911305B1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| ES2471077T3 (es) | Composición de comprimido de ferrimanitol-ovoalb�mina | |
| JP2006510665A (ja) | 新規な経口即時放出型投与剤形 | |
| JP2022072050A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
| ES2960207T3 (es) | Combinación de dosis fijas de liberación inmediata de memantina y donepezilo | |
| KR20210052495A (ko) | 경구 투여용 의약 조성물 | |
| RU2799763C2 (ru) | Способ производства фармацевтической композиции, содержащей нефопам и ацетаминофен, и полученная на их основе фармацевтическая композиция | |
| JP3637968B1 (ja) | 胃内崩壊性錠剤 | |
| WO2010100658A2 (en) | Stable olanzapine tablets and the process for its preparation |